Multiple primary tumours in a population-based series of patients with histopathologically peer-reviewed sarcomas. by Hartley, A. L. et al.
Br. .1. Cancer (1993), 68, 1243-1246
Multiple primary tumours in a population-based series of patients with
histopathologically peer-reviewed sarcomas
A.L. Hartley', V. Blair', M. Harris2, J.M. Birch', S.S. Banerjee2, A.J. Freemont3, J. McClure3 &
L.J. McWilliam3
'Cancer Research Campaign Paediatric and Familial Cancer Research Group, Christie Hospital NHS Trust, Manchester M20
9BX; 2Department ofPathology, Christie Hospital NHS Trust, Manchester M20 9BX; 3Department ofPathological Sciences,
University ofManchester, Manchester M13 9PL, UK.
Summary Multiple primary tumours occurring in a three-year population-based series of patients with
histopathologically peer-reviewed sarcomas from North West England were ascertained in order to look at the
patterns of neoplasms seen. A total of 30 out of the 310 patients entered in the study had additional primary
tumours. Very few patients were aged under 60 years at diagnosis of both their malignancies. The youngest
was a known case of neurofibromatosis and, although seven patients were diagnosed with a sarcoma and
carcinoma of the breast - a combination of cancers characteristic of the Li-Fraumeni cancer family syndrome
- no other patients could directly be identified as suffering from any other cancer predisposition synd-
rome.
The occurrence of multiple primary cancers in an individual
may happen by chance or may indicate that these neoplasms
have shared aetiological risk factors or that treatment for one
cancer may be directly related to the subsequent development
of a second tumour. Alternatively, multiple primary cancers
may be a result of genetic predisposition to malignancy in
relation to conditions such as neurofibromatosis, Gorlin's
syndrome, multiple endocrine neoplasia, Beckwith-Weide-
mann syndrome, or to various cancer family syndromes
(Schottenfeld, 1982; Birch, 1987). Sarcomas, in particular, are
important components of at least two inherited cancer-prone
conditions - neurofibromatosis (Hope & Mulvihill, 1981) and
Li-Fraumeni syndrome (LFS) (Li et al., 1988).
Studies have indicated that second primary tumours are
diagnosed to excess in survivors of childhood sarcoma and
that their occurrence may act as a marker for excesses of
cancers characteristic of the LFS in close relatives (Strong et
al., 1987; Burke et al., 1991). A number of children and
young adults with double primary neoplasms, including sar-
comas, but without an apparent family history of LFS have
also been shown to carry germ-line mutations in the p53 gene
(Malkin et al., 1992; Toguchida et al., 1992). Such mutations
have been identified in a proportion of families with LFS
(Malkin et al., 1990; Santibiafiez-Koref et al., 1991).
The North West Sarcoma Incidence Study, which relates
to a unique population-based series of patients of all ages
with sarcoma, was established to look at the effects of histo-
pathological peer-review, and at incidence and survival.
Another important aim was to assess the patterns of multiple
primary neoplasms occurring in these patients in relation to
the presence of possible inherited predisposition to cancer in
the population with a view to identifying families for further
study.
Patients and methods
Patients eligible for the study were those diagnosed with
sarcomas in the years 1982-84 inclusive who were resident in
the North Western Regional Health Authority area at time
ofdiagnosis and who were registered with the North Western
Regional Cancer Registry (NWRCR). Sarcomas included in
the study were those malignant soft tissue tumours (including
those of visceral sites) given in the modified WHO scheme
described by Enzinger and Weiss (1988) together with
osteosarcoma, chondrosarcoma, Ewing's tumour and other
primary sarcomas of bone.
Ascertainment for the NWRCR is via registrations submit-
ted by peripatetic clerks, hospitals and general practitioners,
and from death notifications supplied by the Office of
Population Censuses and Surveys. Completeness of cancer
registration in the North Western Region was assessed in
1981-82 at 95% overall for cases with anniversary year
1974-77, and was greatest for the cancers with poorest
survival and for patients treated at specialist centres (Nwene
& Smith, 1982). Since patients with sarcomas may be referred
to specialist centres for treatment and because of their high
mortality, there is no reason to assume a registration level for
sarcomas below the 95% level. Full details of ascertainment
for the study are given elsewhere (Hartley et al., 1991).
Histopathological material was requested for each case
together with a copy of the original histology report. Sections
were stained initially with haematoxylin and eosin and cir-
culated to the five panel pathologists (each of whom had a
special interest in sarcomas), together with a brief clinical
summary of the case. Panel members recorded their diag-
noses individually without discussion or knowledge of the
original histology. Where there was any disagreement bet-
ween members' diagnoses, the final (panel) diagnosis was
arrived at by consensus and, if necessary, after the applica-
tion of special stains including immunohistochemistry. A
detailed description of the review method and special stains
used has been reported (Harris et al., 1991). Final sarcoma
diagnoses were coded using ICD-O (WHO, 1976).
All second primary cancers are cross-referenced with the
initial primary tumour registration in the NWRCR records
and hence details on most additional cancers were obtained
in this way. Cancers occurring prior to incident sarcoma
diagnosis were recorded for the study at the time of sarcoma
ascertainment from the Register. In addition, in certain cases
the diagnosis of a previous tumour occurring prior to cancer
registration (1962 in the NW region) was mentioned on the
sarcoma pathology report form. Prior tumours, however, are
likely to be underascertained.
Cancers occurring after diagnosis of sarcoma were
identified by subsequent scrutiny of the original registration
for sarcoma. To provide an additional check and to enable
ascertainment of second cancers in those patients who may
have moved out of the NW region, surviving patients were
also 'flagged' on the National Health Service Central
Register. Again, however, because of the time lag in registra-
tion procedures second cancers are subject to under-ascer-
tainment.
Hospital notes were scrutinised, where still available, for
all patients with multiple primary tumours and additional
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histopathology review was undertaken in some cases where
there was doubt that a prior or subsequently-registered
cancer was an independent primary tumour.
In order to assess whether patients were at excess risk of
developing other malignancies after their diagnosis of sar-
coma, observed numbers of malignancies were compared
with expected numbers. Expected numbers of malignant and
central nervous system tumours (excluding non-melanoma
skin cancers) were calculated using sex- and 5-year age
group-specific rates for the period 1980-84 derived from
NWRCR statistics. The period of risk was taken as the time
from diagnosis of sarcoma (if under age 75 years) up to the
earliest of the following dates: 30th June 1990 (to allow for
time-lag in cancer registration), date of last follow up, date of
death or date of 75th birthday. Observed numbers of cancers
were compared with expected numbers and one-tailed Pois-
son probabilities and 95% confidence intervals for the
relative risks calculated. To allow for synchronous tumours,
the analysis was repeated but with the period of risk starting
6 months after diagnosis of sarcoma. The computer package
Epilog Plus version 2 (1987) was used for all the statistical
analyses.
Results
Out of a total of 59,784 cancer registrations for the North
Western Region for the years 1982-84, 315 patients were
confirmed as having sarcomas on panel review (Harris et al.,
1991). Five of the 315 confirmed cases were subsequently
excluded from this investigation; four were found to have
been resident outside the NWRCR area when originally diag-
nosed, and one had diagnosis date incorrectly notified. Table
I shows distribution by histological type for the 310 cases
included in the study. Age range of the cohort of 310 sar-
coma patients entered in the study was 0-95 years. Median
age at diagnosis was 61 years for males, 57 years for females
and 59.5 years overall. Mean length of follow up for all cases
combined was 3.8 years.
A total of 30 out of 310 cases had at least one additional
primary tumour (Table II). In 14 cases the incident sarcoma
was an initial primary and in another 14 cases the sarcoma
Table I Distribution of cases by histological type
Histology Male Female Total
Soft tissue sarcomas
Leiomyosarcoma 23 48 71
Malignant fibrous histiocytoma 25 24 49
Sarcoma NOS 21 13 34
Liposarcoma 7 14 21
Malignant peripheral nerve 7 5 12
sheath tumour
Rhabdomyosarcoma 7 4 11
Haemangiosarcoma 6 4 10
Other specified soft tissue sarcoma 13 32 45
Total soft tissue sarcoma 109 144 253
Bone tumours
Osteosarcoma 14 10 24
Chondrosarcoma 15 7 22
Ewing's tumour 3 4 7
Other specified bone tumours 3 1 4
Total bone tumours 35 22 57
Total sarcomas 144 166 310
Table H Multiple primary tumours in sarcoma patients
Age at Age at Age at
Case diagnosis diagnosis diagnosis No. Sex Previous tumour(s) (years) Sarcoma (years) Subsequent tumour(s) (years)
I F Astrocytoma 33 MPNST axilla 34
2 F Carcinoma breasta 39 Extra-skeletal 39
chondrosarcoma
paraspinal 3 F Sarcoma NOS chest wall 47 Carcinoma pancreasa 47 4 F Carcinoma ?ovary 46 Fibrosarcoma thigh 53
5 F Clear cell sarcoma leg 55 Carcinoma rectum 61 6 F Carcinoma breast 53 Sarcoma NOS uterus 55
7 M Seminoma testis 31 Sarcoma NOS liver 56
8 F MFH arm 56 Carcinoma bladderb 63 9 F Dermatofibrosarcoma 62 Carcinoma breastb 72
protuberans abdominal
wall
10 F Leiomyosarcoma uterus 46 Chondrosarcoma humerus 63
11 F MFH back 67 Carcinoma breast 68 12 M Leiomyosarcoma arm 67 Carcinoma oesophagus 68 13 F Carcinoma ovarya 68 MFH breast 68
14 M MFH thigh 68 Carcinoma lung 75 15 M MFH arm 70 Carcinoma lung 71 16 F Carcinoma cervix 64 Chondrosarcoma ischium 70
17 F Angiosarcoma leg 70 Carcinoma breast 80 18 F Carcinoma breast 63 MFH abdominal wall 71
19 M SCC hand 71 Leiomyosarcoma arm 72 Carcinoma lunga 72 20 F MFH thigh 72 BCC arm 78 21 F Leiomyosarcoma arm 72 Carcinoma colon 80 22 M Carcinoma colon 71 Leiomyosarcoma calf 73
23 M MFH groin 74 SCC lower lipa 74 24 M Testicular tumour NOS 47 Liposarcoma scrotum 75 Multiple BCC scalp 76
Carcinoma vocal cord 81 25 F Meningioma 64 MFH neck 75 26 M Carcinoma colon 72 Angiosarcoma scalp 76 27 F Carcinoma uterus 68 Leiomyosarcoma scalp 79 28 M Leiomyosarcoma thigh 82 Carcinoma ?lung 85 29 F MFH calf 84 Carcinoma breasta 84 30 F BCC cheek 50 Osteosarcoma femur 94
Carcinoma cervix 67
BCC - basal cell carcinoma; MFH - malignant fibrous histiocytoma; MPNST -malignant peripheral nerve sheath tumour; NOS -
not otherwise specified; SCC - squamous cell carcinoma. Tumours diagnosed within 6 months of diagnosis of sarcoma. bDiagnosed after formal date of last follow up.MULTIPLE TUMOURS IN SARCOMA PATIENTS 1245
developed subsequent to a previously diagnosed tumour.
Cases 19 and 24 each had other primary tumours diagnosed
pre- and post-sarcoma. In six patients an additional primary
tumour was diagnosed within six months of diagnosis of
sarcoma. The most common sarcomas occurring as initial
primary tumours were malignant fibrous histiocytoma
(MFH) (7 cases) and leiomyosarcoma (three cases). The
second malignancies in this group of patients included four
carcinomas of respiratory tract, four of breast and three of
gastro-intestinal tract. In the 16 patients diagnosed with a
sarcoma subsequent to a previous tumour, there was a more
diverse distribution of sarcoma sub-type. The initial tumours
in these patients included a previous leiomyosarcoma of the
uterus, seven other tumours of genito-urinary tract, three
breast cancers, two colon cancers and two brain tumours.
Additional primary tumours were diagnosed at ages ranging
from 31-85 years.
The youngest patient in the study to be diagnosed with a
sarcoma and an additional primary cancer (case 1) was
known to suffer from neurofibromatosis. One patient had
two sarcomas (case 10) and seven patients were diagnosed
with carcinoma of the breast in addition to their sarcoma
(cases 2, 6, 9, 11, 17, 18 and 29).
A total of 261 patients (125 males and 136 females) and
seven cancers were eligible to be included in analysis of risk
of developing other malignancies after diagnosis of sarcoma.
The observed cancers were in excess of those expected but
the excess was not statistically significant (person years at
risk = 807, obs = 7, exp = 4.58, RR = 1.5, 95% CI 0.6-3.1,
P = 0.2). Analysis by sex, age at diagnosis (<60 years and
60 + years) and by histological sub-type of sarcoma similarly
did not reveal any significant excesses of second cancers.
Exclusion of second malignancies and years of follow-up
within 6 months ofdiagnosis of sarcoma resulted in an excess
risk of 1.06 (person years at risk = 692, obs = 4, exp = 3.77,
95% CI 0.3-2.7, P = 0.5).
Discussion
The study reveals that very few younger patients had mul-
tiple primary tumours involving sarcomas. Only two patients
in the three-year series were under the age of 45 years, and
six patients under the age of 60 years at the time ofdiagnosis
of both their malignancies. The youngest case with a double
primary cancer was a known case of neurofibromatosis but
this syndrome, although registrable under cancer registration
schemes, was not recorded on the registration form for any
other patient in the study who developed a second primary
tumour.
Ascertainment of patients with multiple primary cancers
may lead to the identification of families with the Li-
Fraumeni syndrome (LFS), a syndrome characterised by the
development of sarcomas in children and young adults
together with early onset cancers in their close relatives and
in which multiple primary tumours frequently occur.
Although seven patients in the series had a sarcoma and
carcinoma of the breast, a classic combination of cancers in
the LFS, only two of these patients were aged under 60
years, the age by which the majority of LFS cancers occur, at
diagnosis of both tumours. There were no other obvious
combinations of LFS-type cancers, e.g. sarcoma and brain
tumour or sarcoma and leukaemia/lymphoma, in any
younger patients and it seems unlikely that any other than a
small proportion of the study population may have been
affected by this syndrome. However, as more than 50 of the
study population are still under the age of 60 years, a full
family history of cancer for each patient would be necessary
to define patients affected by the syndrome and who may be
at risk of second malignancy.
It is clear that double primary cancers involving sarcomas
are extremely rare in the general population and that few
patients with syndromes predisposing to sarcomas and other
cancers can be directly identified from cancer registrations.
Many double primaries of this nature may simply be chance
occurrences in patients of advancing age - data from this
same population have shown that incidence of sarcomas in
general increases with age to peak between 70-74 years
(Hartley et al., 1991).
As a result of the relatively small sample size, short mean
period of follow up and high mortality resulting from sar-
coma (Hartley et al., 1992), ability to assess risk of develop-
ing a further malignancy after diagnosis of sarcoma is
limited. However, the establishment of a unique population-
based series of sarcomas clearly defined by histopathological
review is an important resource for further studies. Peer
review is an essential pre-requisite for any investigation of
this kind as reclassification of sarcomas is a consistent occur-
rence (Presant et al., 1986; Harris et al., 1991). Follow-up of
the study cohort via the NWRCR and NHSCR over a period
of time will enable assessment of risk of subsequent cancer
and will also identify those patients with early onset double
primaries who may then form the subjects offurther work on
genetic predisposition to cancer.
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